NEXTBio Capital Management LP Makes New Investment in Vor Biopharma Inc. $VOR

NEXTBio Capital Management LP acquired a new position in Vor Biopharma Inc. (NASDAQ:VOR) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 999,967 shares of the company’s stock, valued at approximately $13,080,000. Vor Biopharma makes up 7.7% of NEXTBio Capital Management LP’s investment portfolio, making the stock its 3rd biggest holding. NEXTBio Capital Management LP owned 9.61% of Vor Biopharma at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Vor Biopharma in the 4th quarter worth about $36,000. Bank of America Corp DE boosted its holdings in shares of Vor Biopharma by 679.3% in the 3rd quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after purchasing an additional 4,144 shares in the last quarter. Squarepoint Ops LLC purchased a new position in shares of Vor Biopharma in the 3rd quarter worth about $230,000. BNP Paribas Financial Markets boosted its holdings in shares of Vor Biopharma by 497.3% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after purchasing an additional 5,058 shares in the last quarter. Finally, Bridgeway Capital Management LLC purchased a new position in shares of Vor Biopharma in the 3rd quarter worth about $304,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the company. Wedbush upped their price objective on Vor Biopharma from $15.00 to $18.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Jefferies Financial Group upgraded Vor Biopharma to a “strong-buy” rating in a report on Thursday, April 30th. Wells Fargo & Company assumed coverage on Vor Biopharma in a report on Thursday, March 19th. They issued an “overweight” rating and a $30.00 price objective for the company. Wall Street Zen cut Vor Biopharma from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Vor Biopharma in a report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $42.25.

Insiders Place Their Bets

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of the stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the sale, the director directly owned 2,402,095 shares in the company, valued at $37,881,038.15. This represents a 6.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. In the last three months, insiders sold 3,002,903 shares of company stock worth $49,412,176. Corporate insiders own 0.27% of the company’s stock.

Vor Biopharma Stock Performance

Shares of VOR stock opened at $14.36 on Friday. Vor Biopharma Inc. has a 1-year low of $3.63 and a 1-year high of $65.80. The business has a 50-day moving average of $15.09 and a 200 day moving average of $13.90.

Vor Biopharma (NASDAQ:VOR) last issued its earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. As a group, equities analysts anticipate that Vor Biopharma Inc. will post -2.51 EPS for the current year.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).